Skip to main content

Table 3 Summary of safety (safety population): post-hoc analysis

From: Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis

  Ambrisentan
CTD-PAH
(N = 71)
IPAH/HPAH
(N = 51)
Any AEs, n (%) 52 (73.2) 31 (60.8)
 AEs related to study treatment 28 (39.4) 17 (33.3)
 Discontinuation due to AE 1 (1.4) 2 (3.9)
Any serious AEs, n (%) 6 (8.5) 3 (5.9)
Deaths, n (%) 1 (1.4) 1 (2.0)
Most frequent (≥5% in either subgroup) AEs, n (%)
 Flushing 9 (12.7) 2 (3.9)
 Oedema peripheral 7 (9.9) 8 (15.7)
 Headache 6 (8.5) 0
 Decreased appetite 5 (7.0) 1 (2.0)
 Dizziness 5 (7.0) 1 (2.0)
 Nausea 5 (7.0) 2 (3.9)
 Alanine aminotransferase increased 4 (5.6) 5 (9.8)
 Blood bilirubin increased 4 (5.6) 5 (9.8)
 Blood glucose increased 2 (2.8) 3 (5.9)
 Cough 4 (5.6) 2 (3.9)
 Gamma glutamyltransferase increased 4 (5.6) 3 (5.9)
 Aspartate aminotransferase increased 3 (4.2) 6 (11.8)
  1. AE adverse event, CTD connective tissue disease, HPAH Heritable PAH, IPAH Idiopathic PAH, PAH pulmonary arterial hypertension
\